SIREN : 508052008
MEDIPREIM is a French company founded 17 years ago, specialized in the sector Location de terrains et d'autres biens immobiliers. Based in PARIS (75008), this company of category ETI shows in 2024 a revenue of 8.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 284 361 € | 8 284 134 € | 8 297 741 € | 9 611 211 € | 10 014 480 € | 10 004 731 € | 9 762 047 € | 9 715 271 € | 4 785 467 € |
| Net income | 18 415 779 € | 17 460 444 € | 22 864 222 € | 18 063 698 € | 13 225 999 € | -4 936 190 € | 13 320 194 € | 18 065 603 € | -370 980 € |
| EBITDA | 6 772 840 € | 6 670 918 € | 5 874 172 € | 7 866 234 € | 8 602 993 € | 8 296 806 € | 7 964 874 € | 7 937 608 € | 3 963 064 € |
| Net margin | 222.3% | 210.8% | 275.5% | 187.9% | 132.1% | -49.3% | 136.4% | 186.0% | -7.8% |
In 2024, MEDIPREIM achieves revenue of 8.3 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +7.1%. Vs 2023: +0%. After deducting consumption (0 €), gross margin stands at 8.3 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 6.8 M€, representing 81.8% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 18.4 M€, i.e. 222.3% of revenue. This profit can be retained or distributed to shareholders.
8 284 361 €
8 284 361 €
6 772 840 €
5 764 955 €
18 415 779 €
81.8%
The debt ratio (= Financial debt / Equity x 100) stands at 156%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 10.4 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 209.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
155.898%
39.036%
209.296%
10.396
73.2%
In 2024, the debt ratio of MEDIPREIM (155.90) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MEDIPREIM (39.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of MEDIPREIM (10.40) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 15214.08. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 70.7x. Operating income very largely covers interest expenses: high safety margin.
15214.082
70.688
In 2024, the liquidity ratio of MEDIPREIM (15214.08) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of MEDIPREIM (70.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 2 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 75 days. Excellent situation: suppliers finance 73 days of the operating cycle (retail model). Overall, WCR represents 1910 days of revenue, i.e. 44.0 M€ to permanently finance. Notable WCR improvement over the period (-65%), freeing up cash.
43 953 754 €
2 j
75 j
0 j
1910 j
Based on 169 transactions of similar company sales in 2024, the value of MEDIPREIM is estimated at 46 066 329 € (range 13 332 038€ - 83 122 020€). With an EBITDA of 6 772 840€, the sector multiple of 5.6x is applied. The price/revenue ratio is 0.81x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 169 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDIPREIM with other companies in the same sector:
Voir toutes les statistiques du secteur Location de terrains et d'autres biens immobiliers
The revenue of MEDIPREIM in 2024 is 8.3 M€.
Yes, MEDIPREIM generated a net profit of 18.4 M€ in 2024.
The headquarters of MEDIPREIM is located in PARIS (75008), in the department Paris.
The tax return of MEDIPREIM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDIPREIM operates in the sector Location de terrains et d'autres biens immobiliers (NAF code 68.20B). See the 'Sector positioning' section above to compare the company with its competitors.